Targeting interleukin-6 could help relieve immunotherapy side effects
Researchers have identified a novel strategy to reduce immune-related adverse events from immunotherapy treatment by targeting the cytokine interleukin-6 (IL-6).
Materials provided by University of Texas M. D. Anderson Cancer Center. Note: Content may be edited for style and length.
Source link aaaaa